Arana expands clinical research
Monday, 28 July, 2008
Arana Therapeutics (ASX: AAH) has appointed former Quintiles executive Dr Alan Scott as its new vice president of clinical research.
The Sydney-headquartered biotech, the result of a merger between Peptech and EvoGenix last year, is commencing several new clinical trials in the next 18 months.
Arana's next scheduled clinical trial will be a Phase II rheumatoid arthritis dose-ranging study for its leading anti-inflammatory compound ART621, which is expected to start in the fourth quarter of this year.
Scott holds a PhD from Glasgow University, did a post-doc in biochemistry at Oxford and has held positions in clinical operations and project management in Europe in the pharma, biotech and CRO sectors.
He was director of site start up for Quintiles in the Asia-Pacific region.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
